 |
|
|
|
|
Table of Contents
- CHAPTER 1 EXECUTIVE SUMMARY
- Key findings
- Historical and forecast branded pharmaceutical sales performance
- Therapeutic strategy
- Launch and expiry outlook
- Externalization, geographic and molecule type strategies
- Externalization strategy
- Geographic strategy
- Molecule type strategy
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- CHAPTER 2 CORPORATE HISTORY
- Key findings
- Background
- Key corporate developments
- M&A history
- Current corporate structure
- Branded pharmaceuticals
- Generics
- CHAPTER 3 HISTORICAL PERFORMANCE
- Key findings
- Introduction
- Revenue and growth rate analysis, 2001-06
- Revenue and growth rate vs. peer set
- Product analysis, 2001-06
- Growth drivers
- Coversyl
- Bipreterax
- Vastarel
- Growth resistors
- Operating revenue and cost analysis, 2001-06
- CHAPTER 4 FORECAST PERFORMANCE
- Key findings
- Introduction
- Revenue and growth rate, 2006-12
- Product analysis, 2006-12
- Growth drivers
- Protelos
- Procoralan
- Bipreterax
- Growth resistors
- Therapy area analysis, 2006-12
- Musculoskeletal
- Cardiovascular & hematology
- Therapy area focus
- Launches and expiries analysis, 2006-12
- Launch portfolio
- Procoralan is Servier' s largest ' launch' product
- Valdoxan' s EU launch has been delayed
- Further launches could boost sales
- Core portfolio
- Expiry portfolio
- Launch/core/expiry configuration
- Externalization analysis, 2006-12
- Geographic analysis, 2006-12
- Molecule type analysis, 2006-12
- CHAPTER 5 KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- Cardiovascular & hematology
- Coversyl
- Overview
- Sales forecast
- Newsflow
- Competitive landscape
- Future market assessment
- Daflon
- Overview
- Sales forecast
- Newsflow
- Competitive landscape
- Future market assessment
- Bipreterax
- Overview
- Sales forecast
- Newsflow
- Competitive landscape
- Future market assessment
- Vastarel
- Overview
- Sales forecast
- Newsflow
- Musculoskeletal
- Protelos
- Overview
- Sales forecast
- Newsflow
- Competitive landscape
- Future market assessment
- Endocrine, metabolic & genetic disorders
- Diamicron
- Overview
- Sales forecast
- Newsflow
- Competitive landscape
- R&D pipeline
- CHAPTER 6 APPENDIX
- IMS vs. company-reported data reconciliation
- References
- Abbreviations
- Exchange rates
- List of Tables
- Table 1: Peer set overview
- Table 2: Product portfolio overview, sales ($m), 2006-12
- Table 3: Therapy area overview, sales ($m), 2006-12
- Table 4: Launch portfolio overview, sales ($m), 2006-12
- Table 5: Core portfolio overview, sales ($m), 2006-12
- Table 6: Expiry portfolio overview, sales ($m), 2006-12
- Table 7: Molecule type overview, sales ($m), 2006-12
- Table 8: Key products overview
- Table 9: Coversyl: overview
- Table 10: Coversyl: sales forecast ($m), 2006-12
- Table 11: Coversyl: newsflow
- Table 12: Daflon: overview
- Table 13: Daflon: sales forecast ($m), 2006-12
- Table 14: Daflon: newsflow
- Table 15: Bipreterax: overview
- Table 16: Bipreterax: sales forecast ($m), 2006-12
- Table 17: Bipreterax: newsflow
- Table 18: Vastarel: overview
- Table 19: Vastarel: sales forecast ($m), 2006-12
- Table 20: Vastarel: newsflow
- Table 21: Protelos: overview
- Table 22: Protelos: sales forecast ($m), 2006-12
- Table 23: Protelos: newsflow
- Table 24: Diamicron: overview
- Table 25: Diamicron: sales forecast ($m), 2006-12
- Table 26: Diamicron: newsflow
- Table 27: Servier' s R&D pipeline (Phase I-registration)
- Table 28: Exchange rates, 2006
- List of Figures
- Figure 1: Historical and forecast branded pharmaceutical sales
performance (% CAGR), Servier and Mid Pharma peer set
- Figure 2: Therapeutic focus vs. Mid Pharma peer set (%), 2006
- Figure 3: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), Servier
- Figure 4: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), peer set
- Figure 5: Externalization, geographic market and molecule type
dependency (%) vs. peer set, 2006
- Figure 6: Externalization, geographic market and molecule type
dependency (%) vs. peer set, 2012
- Figure 7: SWOT analysis of Servier
- Figure 8: Servier' s corporate development timeline
- Figure 9: Current corporate structure
- Figure 10: Revenue & growth rate (branded pharmaceutical sales)
($m), 2001-06
- Figure 11: Branded pharmaceutical revenue ($m) and growth rate (%) vs.
peer set, 2001-06
- Figure 12: Growth drivers/resistor products of historical revenue
performance ($m), 2001-06
- Figure 13: Branded pharmaceutical revenue ($m) and growth rate (%),
2006-12
- Figure 14: Top five products by sales ($m), 2006
- Figure 15: Top five products by sales ($m), 2012
- Figure 16: Growth drivers and resistors by product, 2006-12
- Figure 17: Key strategic products, sales ($m), 2006-12
- Figure 18: Branded pharmaceutical sales by therapy area ($m), 2006-12
- Figure 19: Growth drivers and resistors by therapy area ($m), 2006-12
- Figure 20: Branded pharmaceutical sales by therapy area (%), 2006-12
- Figure 21: Therapy area focus compared with peer set (% total branded
pharmaceutical sales), 2006
- Figure 22: Therapy area focus compared with peer set (% total branded
pharmaceutical sales), 2012
- Figure 23: Launch schedule, sales ($m), 2006-12
- Figure 24: Core products sales growth ($m), 2006-12
- Figure 25: Expiry schedule, sales ($m), 2006-12
- Figure 26: Launch, core and expiry, sales ($m), 2006-12
- Figure 27: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), Servier
- Figure 28: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), peer set
- Figure 29: Externalization dependency, sales ($m), 2006-12
- Figure 30: Growth drivers and resistors, externally vs. internally
discovered products, sales ($m), 2006-12
- Figure 31: Externalization dependency vs. peer set, % total sales, 2006
- Figure 32: Externalization dependency vs. peer set, % total sales, 2012
- Figure 33: Geographical sales breakdown ($m), 2006-12
- Figure 34: Growth drivers and resistors by geography, sales ($m),
2006-12
- Figure 35: US dependency vs. peer set, % total sales, 2006
- Figure 36: US dependency vs. peer set, % total sales, 2012
- Figure 37: Molecule type sales breakdown ($m), 2006-12
- Figure 38: Growth drivers and resistors by molecule type, sales ($m),
2006-12
- Figure 39: Biologics dependency vs. peer set, % total sales, 2006
- Figure 40: Biologics dependency vs. peer set, % total sales, 2012
- Figure 41: IMS vs. company-reported ethical sales discrepancy ($m),
2006
- Figure 42: IMS vs. company-reported ethical sales forecast growth
rates (%), 2006-12
|
|
|
|
|
|
View Cart
